Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You?
If you're researching medical weight loss in 2026, your decision usually comes down to two medications: semaglutide (the active ingredient in Ozempic® and Wegovy®) and tirzepatide (the active ingredient in Mounjaro® and Zepbound®). Both are clinically studied, both are prescribed widely for weight management — but they work differently, cost differently, and suit different people.
The quick answer
Semaglutide is the proven workhorse: a GLP-1 receptor agonist with years of real-world use, strong clinical trial results, and generally lower cost. Tirzepatide is the newer dual-action option: it targets both GLP-1 and GIP receptors, produced greater average weight loss in clinical trials, and typically costs more. Neither is "better" universally — the right choice depends on your health history, goals, budget, and how your body responds. That's a decision for you and a licensed provider.
How they work
Both medications mimic gut hormones called incretins, which your body releases after eating:
- Semaglutide activates GLP-1 receptors — reducing appetite, slowing stomach emptying, and quieting the constant "food noise" many people describe.
- Tirzepatide activates GLP-1 receptors and GIP receptors. The dual mechanism appears to enhance the metabolic effect, which may explain the larger average weight loss seen in trials.
What the clinical trials showed
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 | GLP-1 + GIP (dual) |
| Average weight loss in key trials* | ~15% of body weight (STEP trials, 68 weeks) | ~20%+ at higher doses (SURMOUNT trials, 72 weeks) |
| Dosing | Once-weekly injection (oral forms available) | Once-weekly injection |
| Typical cost | Lower | Higher |
*Trial averages with lifestyle intervention; individual results vary widely and are not guaranteed. Sources: STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022).
Side effects
Both share a similar side-effect profile, most commonly gastrointestinal: nausea, constipation, diarrhea, and reduced appetite — typically strongest when starting or increasing dose, and usually improving over weeks. Both carry rare but serious risks including pancreatitis and a boxed warning related to thyroid C-cell tumors observed in rodent studies. Neither is appropriate during pregnancy or with certain conditions like a personal/family history of medullary thyroid carcinoma. A licensed provider screens for all of this before prescribing. See our Important Safety Information.
How to choose
- Budget-first: semaglutide (especially oral) is usually the affordable entry point.
- Results-first: tirzepatide's trial numbers were stronger on average.
- Needle-averse: oral semaglutide exists; tirzepatide is injection-only.
- History with GLP-1s: if semaglutide plateaued for you, providers sometimes consider switching to tirzepatide.
Ultimately, the medication decision belongs to the licensed provider who reviews your health history — which is exactly how it should be.
See which medication you may qualify for
Take the free 2-minute quiz. A US-licensed provider reviews every intake.
Take the QuizThis article is for general education only and is not medical advice. Medications described are prescription-only and are prescribed solely at the discretion of an independent, licensed medical provider. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. Individual results vary and are not guaranteed. Brand names are trademarks of their respective owners; LightenMD is not affiliated with them.